About SomaSignal™ Tests
By measuring thousands of proteins at a time in each blood sample with the SomaScan® Platform, it is possible to uncover a precise set of specific protein changes that provide information on current status and future trajectory for virtually every disease or condition of interest from that one blood sample. For example, we can find repeatable patterns of protein changes that are associated with clinical indications (e.g., cardiovascular events) or fitness attributes (e.g., VO2 max). Each of these patterns, in turn, becomes the basis of a specific “SomaSignal test” that can be ordered by doctors to help them manage their patients’ health more completely and effectively.
The first seven SomaSignal tests (see below) were made available to ordering physicians in a limited number of clinical practices in the Denver, Colorado area in September, 2019. We are working closely with these physicians to maximize the benefit of these tests to their patients, and to take our learnings into additional practices and geographic areas.
We anticipate adding additional provider locations (and additional SomaSignal tests across many other diseases and conditions) regularly over the coming months. To be informed when new sites and tests are added, or to inquire about using SomaSignal tests in your practice or business, please contact us (button to the right).
Current SomaSignal tests in clinical use:
Want more information about our SomaSignal tests?
All SomaSignal test results are derived from the SomaScan Platform, which is deployed in an accredited laboratory at SomaLogic’s headquarters in Boulder, Colorado. The SomaScan Assay and SomaSignal test reports are currently available for Research Use Only worldwide, for Investigational Use Only in certain geographies, and for Commercial Use through a limited number of authorized providers. The SomaSignal tests are developed and their performance characteristics determined by SomaLogic, Inc. They have not been cleared or approved by the US Food and Drug Administration.